Source Articles
Trastuzumab Deruxtecan
Showing 1 study arm
with grade ≥3 adverse event data (treatment-related and RT-related).
Click a column header to sort.
Note on patient counts: some articles reported only percentages rather
than absolute numbers. Where this occurred, the number of patients — including those with
grade ≥3 adverse events — was derived by applying the reported percentage to the total arm
size, which may produce a non-integer value. These figures have been rounded to the nearest
integer for display.
| 1st Author | Year | Study Type | Title | DOI | clinical trial number | number of patients | median/mean age | median follow-up [months] | tumor type | treatment setting | drug group | drug name | if other, please specify | number of SBRT courses | intracranial / extracranial | treated site | If other treated site, please specify | median/mean total RT dose [Gy] | minimum total RT dose [Gy] | maximum total RT dose [Gy] | median/mean number of fractions | minimum number of fractions | maximum number of fractions | median/mean dose per fraction [Gy] | minimum dose per fraction [Gy] | maximum dose per fraction [Gy] | toxicity type | patients with acute G>=3 toxicity | patients with late G>=3 toxicity | patients with G>=3 toxicity, timing unspecified | G>=3 AEs | patients with G>=3 AEs | details on G>=3 toxicity | details on G>=3 toxicity in RT field |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ippolito et al. | 2025 | Prospective | Breast CancerTrastuzumab-deruxtecan and radiotherapy: a safety sub-analysis of combart prospective cohort study | 10.1093/oncolo/oyaf229 | Missing | 22 | Missing | 11 | Breast cancer | any | ADC | Trastuzumab Deruxtecan | — | 52 | both | brain, lung, bone, other | Missing | Missing | Missing | Missing | Missing | Missing | Missing | Missing | 3 | 5 | RT-related | 0 | 1 | — | late G3: 1 AE | late G3: 1 pt |
late G3: radionecrosis
|
late G3: radionecrosis
|